Protocol Ledger

NCT05770609 · Phase II · COMPLETED

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Interventional Phase II clinical trial protocol NCT05770609 sponsored by Shanghai Pharmaceuticals Holding Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-19 Enrollment: 53 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05770609
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)53 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05770609
Protocol FieldVerified Registry Value
NCT IdentifierNCT05770609
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment53 participants (ACTUAL)
Registered Start Date2023-06-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI